Recently, biopharmaceuticals are highly anticipated, and devices are required which enable patients to self-administer outside hospitals.
As the biopharmaceuticals have high molecular weights, an innovation is necessary for non-oral administration, such as improving permeability. Subcutaneous administration, such as with a needle-free injector, poses a challenge in that it cannot be applied to pharmaceuticals in large doses, owing to its limited volume being administered in several milliliters. Although longer administration time can increase the volume to be administered, it is less convenient.
Under such a circumstance, both pharmaceutical start-up companies and universities are extensively investigating subcutaneous administration methods for biopharmaceuticals. Therefore, the client has issued this open request to further accelerate its development in collaboration with potential partners.
Technology to concentrate 5–10 mL of drug solution by about five times to reduce the volume of one dose is also welcome.